评价在同期放化疗后以替加氟-尿嘧啶作为节拍式治疗方案治疗非远处转移的 TNM 分期 IV 期鼻咽癌患者的效果。
Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma.
机构信息
Division of Hematology/Oncology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
出版信息
Head Neck. 2019 Nov;41(11):3775-3782. doi: 10.1002/hed.25904. Epub 2019 Aug 22.
BACKGROUND
The study was aimed to evaluate the impact of accumulated oral tegafur-uracil (UFUR) as maintenance chemotherapy on overall survival (OS) and disease-free survival (DFS) rates after concurrent chemoradiotherapy (CCRT) for complete remission (CR) in non-distant metastatic TNM stage IV nasopharyngeal carcinoma (NPC).
METHODS
Data were retrospectively analyzed from a database of patients with non-distant metastatic TNM stage IV NPC, composed of those who underwent CCRT for CR from January 2010 through December 2017.
RESULTS
Thirty-three patients were treated with CCRT (the non-UFUR group), and the other 37 patients were treated with the same regimen, followed by additional oral UFUR (the UFUR group). Importantly, the 5-year OS rates were 91.89% in the UFUR group and 57.58% in the non-UFUR group (P = .004).
CONCLUSIONS
Adding UFUR to CCRT was found to significantly improve the DFS and OS rates of patients with non-distant metastatic TNM stage IV NPC. The authors cautiously suggest UFUR as possible maintenance therapy following CCRT.
背景
本研究旨在评估在完全缓解（CR）的局部晚期转移性 IV 期鼻咽癌（NPC）患者中，同步放化疗（CCRT）后，累积口服替加氟-尿嘧啶（UFUR）作为维持化疗对总生存（OS）和无病生存（DFS）率的影响。
方法
从 2010 年 1 月至 2017 年 12 月接受 CCRT 治疗 CR 的局部晚期转移性 IV 期 NPC 患者的数据库中回顾性分析数据。
结果
33 例患者接受 CCRT（非 UFUR 组），另外 37 例患者接受相同方案治疗，随后接受口服 UFUR（UFUR 组）。重要的是，UFUR 组的 5 年 OS 率为 91.89%，而非 UFUR 组为 57.58%（P=0.004）。
结论
在 CCRT 中加入 UFUR 可显著提高局部晚期转移性 IV 期 NPC 患者的 DFS 和 OS 率。作者谨慎地建议 UFUR 作为 CCRT 后的可能维持治疗。
Zotero 插件